The European market has recently faced challenges, with the pan-European STOXX Europe 600 Index declining by 3.79% amid heightened geopolitical tensions and soaring energy costs, prompting caution from the European Central Bank regarding inflation risks. In this environment of uncertainty, high-growth tech stocks in Europe are gaining attention for their potential to offer resilience and innovation-driven growth, making them an intriguing focus for investors seeking opportunities in a turbulent market landscape.
|
Name |
Revenue Growth |
Earnings Growth |
Growth Rating |
|---|---|---|---|
|
Hacksaw |
24.17% |
25.33% |
★★★★★★ |
|
Pharma Mar |
16.93% |
29.76% |
★★★★★☆ |
|
Adtraction Group |
4.79% |
101.86% |
★★★★★☆ |
|
Paradox Interactive |
5.65% |
37.82% |
★★★★★☆ |
|
CD Projekt |
33.42% |
28.82% |
★★★★★★ |
|
Appear |
20.02% |
25.75% |
★★★★★★ |
|
Bonesupport Holding |
21.85% |
33.95% |
★★★★★★ |
|
Comet Holding |
12.40% |
56.71% |
★★★★★☆ |
|
SyntheticMR |
18.81% |
47.40% |
★★★★★☆ |
|
Waystream Holding |
12.91% |
40.25% |
★★★★★☆ |
Let’s review some notable picks from our screened stocks.
Simply Wall St Growth Rating: ★★★★★☆
Overview: argenx SE is a commercial-stage biopharmaceutical company focused on developing therapies for autoimmune diseases across multiple regions, including the United States, Japan, China, and the Netherlands, with a market cap of €37.31 billion.
Operations: argenx SE generates revenue primarily through its biotechnology segment, amounting to $4.24 billion. The company focuses on developing therapies for autoimmune diseases across several key international markets.
argenx SE, a standout in the biotech sector, has demonstrated robust financial and operational growth with its innovative treatments for autoimmune diseases. In 2025, the company reported a significant revenue increase to USD 4.25 billion from USD 2.25 billion the previous year, underscoring a growth rate of over 88%. This surge is primarily driven by its flagship product VYVGART®, which has shown promising results in recent Phase 3 trials for various myasthenia gravis subtypes. The firm’s commitment to R&D is evident from its latest presentations at major medical conferences, potentially setting new standards in patient care with targeted therapies. With an earnings growth of approximately 55% last year surpassing industry averages and projected annual profit increases of around 21.6%, argenx is not just enhancing its market position but also shaping future treatment paradigms in neurology and beyond.
Simply Wall St Growth Rating: ★★★★★★
Overview: Hacksaw AB (publ) is a B2B technology platform and game development company operating in Sweden and the Czech Republic, with a market cap of SEK16.87 billion.
Operations: The company generates revenue primarily through providing online casino solutions and related services to gaming operators, amounting to €197.48 million.
Hacksaw Gaming, with a robust annual revenue growth of 24.2% and earnings expansion at 25.3%, outpaces the Swedish market significantly. In its recent strategic moves, Hacksaw secured a new online gaming license in Connecticut and expanded its European footprint by launching with Bonver WIN in the Czech Republic. These developments not only enhance its market presence but also demonstrate Hacksaw’s agility in navigating regulatory landscapes and capitalizing on emerging opportunities in digital gaming. With R&D expenses strategically aligned to foster innovation, evidenced by a substantial increase to €15 million last year, Hacksaw is poised to maintain its momentum through cutting-edge offerings and strategic market expansions.
Simply Wall St Growth Rating: ★★★★★★
Overview: CD Projekt S.A., along with its subsidiaries, is involved in the production, publishing, and digital distribution of video games and related products in Poland, with a market capitalization of PLN24.01 billion.
Operations: CD Projekt generates revenue primarily through its CD PROJEKT RED segment, which accounted for PLN866.99 million. The company is focused on the production and distribution of video games and related products within Poland.
CD Projekt, reflecting a robust trajectory in the tech sector, posted significant financial gains with its latest earnings report showing a revenue increase to PLN 867 million from PLN 798 million year-over-year and net income surging to PLN 595 million from PLN 444 million. This performance is underpinned by an aggressive R&D strategy that fuels innovation, crucial for staying ahead in the competitive gaming industry. The company’s future looks promising with expected annual revenue and earnings growth rates of 33.4% and 28.8% respectively, outpacing the broader Polish market projections significantly.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ENXTBR:ARGX OM:HACK and WSE:CDR.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com